Bayer's $1.1 Bil. Chiron Diagnostics Buy Adds Blood Gas Analyzer Line
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of Chiron Diagnostics for $1.1 bil. provides Bayer with an entry into the blood gas analysis market, broadens clinical laboratory systems offerings and will accelerate development efforts in the field of nucleic acid diagnostics.